Y Intercept Hong Kong Ltd Makes New $2.96 Million Investment in Abbott Laboratories $ABT

Key Points

• Y Intercept Hong Kong Ltd disclosed a new stake in Abbott Laboratories during the first quarter, buying 28,871 shares valued at about $2.96 million.
• Abbott is seeing continued interest from major institutions, with firms like Vanguard, State Street, and Capital International Investors also increasing holdings; roughly 75.18% of the stock is owned by hedge funds and other institutions.
• Abbott reported solid quarterly results, including EPS of $1.15 and revenue of $11.16 billion, and it reaffirmed guidance while declaring a quarterly dividend of $0.63 per share for a 2.6% annualized yield.

Y Intercept Hong Kong Ltd bought a new stake in Abbott Laboratories (NYSE:ABT - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 28,871 shares of the healthcare product maker's stock, valued at approximately $2,964,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares in the last quarter. State Street Corp raised its holdings in shares of Abbott Laboratories by 2.1% during the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock valued at $10,004,880,000 after buying an additional 1,627,791 shares during the period. Capital International Investors lifted its position in Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock worth $7,922,519,000 after acquiring an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP boosted its holdings in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors grew its position in Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock valued at $4,907,523,000 after acquiring an additional 400,400 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the business's stock in a transaction on Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company's stock, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ABT shares. Sanford C. Bernstein decreased their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price objective on the stock. Citigroup decreased their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a "buy" rating for the company in a research report on Friday, April 17th. BTIG Research reaffirmed a "buy" rating and set a $131.00 target price on shares of Abbott Laboratories in a research report on Monday, April 27th. Finally, UBS Group cut their price target on Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating on the stock in a research note on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.42.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $95.80 on Wednesday. The stock has a market capitalization of $166.86 billion, a price-to-earnings ratio of 26.83, a PEG ratio of 1.65 and a beta of 0.61. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company's 50-day simple moving average is $89.10 and its 200-day simple moving average is $103.74. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analysts' expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories's payout ratio is currently 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.